Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.

Breast · 2022 · PMC9619174 · PMID 36327624

Europe PMC DOI

hedged sentence

0.0070

closest p · 0.1× alpha

0.0070

boldest claim

The sentences

a strong trendP = 0.007actually significant

Following that, the DESTINY-Breast03 ( NCT03529110 ) phase III trial found that T-DXd as a second-line treatment for patients with HER2-positive MBC significantly improved PFS and had a strong trend of OS benefit (HR, 0.55; 95% CI, 0.36 to 0.86; P = 0.007) when compared to T-DM1 (HR, 0.28; 95% CI, 0.22 to 0.37; P < 0.001) [ 14 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.